Communiqués Percheron Therapeutics Limited BOERSE MUENCHEN

Actions

AWY0

AU0000317281

Marché Fermé - BOERSE MUENCHEN Autres places de cotation 21:43:05 05/07/2024			Varia. 5j.	Varia. 1 janv.
0,0504 ^EUR	0,00%		+3,70%	+46,51%

29/05	Percheron Therapeutics achève le recrutement pour son essai de phase 2 sur la dystrophie musculaire ; les actions augmentent de 3%.	MT
28/02	Percheron Therapeutics Limited publie ses résultats pour le semestre clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	23/08/22	GL
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	22/08/22	GL
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	22/08/22	AQ
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2	22/06/22	GL
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2	22/06/22	AQ
Antisense Therapeutics : Prospectus	12/04/22	PU
Antisense Therapeutics to present poster at world’s largest NMD conference	09/03/22	GL
Antisense Therapeutics to present poster at world’s largest NMD conference	09/03/22	GL
Antisense Therapeutics : Application for quotation of securities - ANP	27/01/22	PU
Antisense Therapeutics : Quarterly Report and Appendix 4C	26/01/22	PU
Antisense Therapeutics : Application for quotation of securities - ANP	24/12/21	PU
Antisense Therapeutics : Application for quotation of securities - ANP	22/12/21	PU
Antisense Therapeutics : Annual General Meeting Presentation	15/12/21	PU
Antisense Therapeutics : Update - Proposed issue of securities - ANP	23/11/21	PU
Antisense Therapeutics : Morgans rates ANP as Add	02/07/21	AQ
Antisense Therapeutics : Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website	11/06/20	BU
Antisense Therapeutics : ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints	21/05/20	BU
Antisense Therapeutics : Announces Appointment of US-based Consultant Medical Director	27/02/20	BU
Antisense Therapeutics : Appointment of Non-Executive Director (G Pace)	09/11/15	PU
Antisense Therapeutics : ATL1103: Data Presentation at the Society for Endocrinology BES 2015 Conference	04/11/15	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Percheron Therapeutics Limited BOERSE MUENCHEN

Actions

AWY0

AU0000317281

Communiqués

Filtres